



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/735,357	12/12/2003	Yijia P. Bao	02-1227-A	2590
20306	7590	04/22/2009	EXAMINER	
MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP			SISSON, BRADLEY L	
300 S. WACKER DRIVE			ART UNIT	PAPER NUMBER
32ND FLOOR			1634	
CHICAGO, IL 60606				

  

MAIL DATE	DELIVERY MODE
04/22/2009	PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/735,357	BAO ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Bradley L. Sisson	1634	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 13 February 2009.  
 2a) This action is **FINAL**.                  2b) This action is non-final.  
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 1-4,6-11,13,27-37 and 168-172 is/are pending in the application.  
 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.  
 5) Claim(s) \_\_\_\_\_ is/are allowed.  
 6) Claim(s) 1-4,6-8,10,13,27-37 and 168-172 is/are rejected.  
 7) Claim(s) 168-172 is/are objected to.  
 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.  
 10) The drawing(s) filed on 13 February 2009 is/are: a) accepted or b) objected to by the Examiner.  
     Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
     Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
 a) All    b) Some \* c) None of:  
 1. Certified copies of the priority documents have been received.  
 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)          | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ .                                    |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____.   | 6) <input type="checkbox"/> Other: _____ .                        |

## **DETAILED ACTION**

### ***Continued Examination Under 37 CFR 1.114***

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 13 February 2009 has been entered.

### ***Election/Restrictions***

2. Claims 9 and 11 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on 02 March 2007.

### ***Drawings***

3. The drawings were received on 13 February 2009. These drawings are not acceptable.

4. New corrected drawings in compliance with 37 CFR 1.121(d) are required in this application because:

a. The lettering is not of proper size, uniform density, and well-defined in Figure(s) 1-3, 5, 6A-6C, 7A, 7B, 8, 9A-9D, 10A, 10B, 11A, 11B, 12A, 12B, 13A, 13B, 14A-14C, 15A-15D, 16A, 16B, 17A-17D, 19A-19J, 20F, and 21;

- b. The lines are not clean, well-defined, and of uniform thickness in Figure(s) 1-3, 4C, 6B, 6C, 7B, 9B-9D, 10B, 11B, 12B, 13B, 14B, 14C, 15A-15D, 16B, 17B, 17D, 19B, 19D, 19F, 19H, 19J, 20B, 20D, 20F, and 21; and
- c. The images/photographs are not clean and well defined in Fig(s) 4A, 4B, 5, 6A-6C, 7A, 8, 9A, 10A, 11A, 12A, 13A, 14A, 16A, 17A, 17C, 19A, 19C, 19E, 19G, 19I, 20A, 20C, and 20E .

5. Applicant is advised to employ the services of a competent patent draftsperson outside the Office, as the U.S. Patent and Trademark Office no longer prepares new drawings. The corrected drawings are required in reply to the Office action to avoid abandonment of the application. The requirement for corrected drawings will not be held in abeyance.

## **INFORMATION ON HOW TO EFFECT DRAWING CHANGES**

### **Replacement Drawing Sheets**

Drawing changes must be made by presenting replacement sheets which incorporate the desired changes and which comply with 37 CFR 1.84. An explanation of the changes made must be presented either in the drawing amendments section, or remarks, section of the amendment paper. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). A replacement sheet must include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of the amended drawing(s) must not be labeled as “amended.” If the changes to the drawing figure(s) are not accepted by the examiner, applicant will be notified of any required corrective action in the next Office action. No further drawing submission will be required, unless applicant is notified.

Identifying indicia, if provided, should include the title of the invention, inventor’s name, and application number, or docket number (if any) if an application number has not been assigned to the application. If this information is provided, it must be placed on the front of each sheet and within the top margin.

### **Annotated Drawing Sheets**

A marked-up copy of any amended drawing figure, including annotations indicating the changes made, may be submitted or required by the examiner. The annotated drawing sheet(s) must be clearly labeled as “Annotated Sheet” and must be presented in the amendment or remarks section that explains the change(s) to the drawings.

### **Timing of Corrections**

Applicant is required to submit acceptable corrected drawings within the time period set in the Office action. See 37 CFR 1.85(a). Failure to take corrective action within the set period will result in ABANDONMENT of the application.

If corrected drawings are required in a Notice of Allowability (PTOL-37), the new drawings MUST be filed within the THREE MONTH shortened statutory period set for reply in the “Notice of Allowability.” Extensions of time may NOT be obtained under the provisions of 37 CFR 1.136 for filing the corrected drawings after the mailing of a Notice of Allowability.

### ***Claim Objections***

6. Claims 168-172 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. Claim 1, the sole independent claim, is directed to a method of detecting the presence of an antibiotic-resistant *Staphylococcus* bacteria from total unamplified *Staphylococcus* genomic DNA. The aspect of detecting and distinguishing additional species of bacteria, bacteria which do not necessarily belong to the named genus, effectively broadens the scope of claim 1.

### ***Claim Rejections - 35 USC § 112***

7. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it

Art Unit: 1634

pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

8. Claims 1-4, 6-8, 10, 13, 27-37, and 168-172 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. As set forth in *Enzo Biochem Inc., v. Calgene, Inc.* (CAFC, 1999) 52 USPQ2d at 1135, bridging to 1136:

To be enabling, the specification of a patent must teach those skilled in the art how to make and use the full scope of the claimed invention without 'undue experimentation.' " *Genentech, Inc. v. Novo Nordisk, A/S*, 108 F.3d 1361, 1365, 42 USPQ2d 1001, 1004 (Fed. Cir. 1997) (quoting *In re Wright*, 999 F.2d 1557, 1561, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993)). Whether claims are sufficiently enabled by a disclosure in a specification is determined as of the date that the patent application was first filed, see *Hybritech, Inc. v. Monoclonal Antibodies, Inc.*, 802 F.2d 1367, 1384, 231 USPQ 81, 94 (Fed. Cir. 1986).... We have held that a patent specification complies with the statute even if a "reasonable" amount of routine experimentation is required in order to practice a claimed invention, but that such experimentation must not be "undue." See, e.g., *Wands*, 858 F.2d at 736-37, 8 USPQ2d at 1404 ("Enablement is not precluded by the necessity for some experimentation . . . However, experimentation needed to practice the invention must not be undue experimentation. The key word is 'undue,' not 'experimentation.' ") (footnotes, citations, and internal quotation marks omitted). In *In re Wands*, we set forth a number of factors which a court may consider in determining whether a disclosure would require undue experimentation. These factors were set forth as follows: (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims. *Id.* at 737, 8 USPQ2d at 1404. We have also noted that all of the factors need not be reviewed when determining whether a disclosure is enabling. See *Amgen, Inc. v. Chugai Pharm. Co., Ltd.*, 927 F.2d 1200, 1213, 18 USPQ2d 1016, 1027 (Fed. Cir. 1991) (noting that the *Wands* factors "are illustrative, not mandatory. What is relevant depends on the facts.").

The quantity of experimentation necessary

The quantity of experimentation necessary to enable the full scope of the claimed invention is great- on the order of several man-years, and then with little, if any, reasonable expectation of success.

The amount of direction or guidance presented / the presence or absence of working examples

The specification has been found to provide the following 7 examples:

- Example 1, pp. 36-47, “Single-step and two-step hybridization methods for identifying SNPs in unamplified genomic DNA using Nanoparticle probes,” (emphasis in the original);
- Example 2, pp. 48-49, “Hybridization Conditions for method of the invention,”
- Example 3, pp. 50-58, “Preparation f [*sic; of*] nanoparticle-oligonucleotide conjugated probes,”
- Example 4, pp. 58-60, “Detection of *mecA* gene sequences from bacterial genomic DNA with gold nanoparticle probes,”
- Example 5, pp. 60-62, “Staphylococcal speciation using bacterial genomic DNA and gold nanoparticle-labeled Tuf probes,”
- Example 6, pp. 62-64, “Staphylococcal speciation and methicillin Resistance assay using PCR amplicons and gold nanoparticles labeled *mecA* and Tuf oligonucleotides as detection probes;” and
- Example 7, pp. 64-65, “Staphylococcal speciation and methicillin resistance assay using genomic DNA and gold nanoparticle-labeled *mecA*, 16S and Tuf probes.”

Art Unit: 1634

Of the seven examples provided, only Example 4 relates to the claimed invention. Upon review of the disclosure, it is noted with particularity that applicant was only able to achieve a detectable result when a specific signal amplification step was performed. The claimed method does not recite such a limitation. In support of this position, attention is directed to page 58 of the disclosure wherein is stated:

At the target amounts tested (250 ng (7.5 E7copies) - 1 ug (3.0 E8)), the attached nanoparticles could not be visualized with the naked eye. In order to facilitate the visualization of nanoparticles hybridized to the substrate surface, a signal amplification method in which silver ions are catalytically reduced by hydroquinone to form silver metal on the slide surface was employed.

And at page 60 of the specification, applicant states:

The reaction mixture was heated to 95 °C for 5 minutes. Subsequently, 10- 25 ul of the reaction mixture was added to the microarray surface and hybridized at 40 °C and 90 % relative humidity for 2 hours. The microarray surface was washed for 30 sec in 5X SSC, 0.05 % TWEEN 20 at room temperature, then washed for another 30 sec with 0.5 M NaNO<sub>3</sub> also at room temperature. The microarray was dried and exposed with silver development using commercial grade silver enhancer solutions (Silver Enhancer Kit, Catalog No. SE-100, Sigma, St. Louis) for 4 minutes. The silver stained microarray plate was then washed, dried and imaged using an Arrayworx® scanner (Model No. AWE, Applied Precision, Inc., Issaquah, WA). (Emphasis added.)

A review of the disclosure fails to find where applicant contemplated alternative test conditions and detection methodologies, much less describe such alternative embodiments so as to reasonably suggest that they had possession of the full genus of methods encompassed by the claims.

#### The nature of the invention

Art Unit: 1634

The method also relates to performing amplification of the target nucleic acid, and that the amplification can be performed under virtually any condition, and any number of cycles.

The claimed invention also relates to sequencing a target nucleic acid.

The claimed invention also relates to the isolation and analysis of genomic DNA as found in a heterogeneous mixture.

The claimed invention also relates to the manufacture, use, and interpretation of data from arrays of capture probes, as well as the synthesis and use of detector probes, which again could be of virtually length.

The state of the prior art / the predictability or unpredictability of the art

Prior, as well as post-filing art teaches of numerous problems confronting those of ordinary skill in the art. These problems have not been addressed by the instant disclosure. Absent specific guidance as to how these issues are to be overcome, one of ordinary skill in the art would be forced to trial-and-error experimentation in an effort to overcome these known issues.

Zhang et al., *Bioinformatics*, Vol. 19, No. 1, 2003, page 14, states:

It is widely recognized that the hybridization process is prone to errors and that the future of DNA sequencing by hybridization is predicated on the ability to successfully cope with such errors. However, the occurrence of hybridization errors results in the computational difficulty of the reconstruction of DNA sequencing by hybridization. The reconstruction problem of DNA sequencing by hybridization with errors is a strongly NP-hard problem. So far the problem has not been solved well.

Chan (US Patent Application Publication US 2002/0119455 A1):

[0018] In practice, Probe Up methods have been used to generate sequences of about 100 base pairs. Imperfect hybridization has led to difficulties in generating adequate sequence. Error in hybridization is amplified many times. A 1% error rate reduces the maximum length that can be sequenced by at least 10%. Thus if 1% of 65,536

oligonucleotides gave false positive hybridization signals when hybridizing to a 200-mer DNA target, 75% of the scored "hybridizations" would be false (Bains, 1997). Sequence determination would be impossible in such an instance. The conclusion is that hybridization must be extremely effective in order to generate reasonable data. Furthermore, sequencing by hybridization also encounters problems when there are repeats in sequences that are one base less than the length of the probe. When such sequences are present, multiple possible sequences are compatible with the hybridization data. (Emphasis added.)

Barany et al. (US 2007/0042419 A1), at paragraph 0036 teaches in part:

For allele-specific oligonucleotide hybridization ("ASO"), the mutation must be known, hybridization and washing conditions must be known, cross-reactivity is difficult to prevent, closely-clustered sites due to interference of overlapping primers cannot undergo multiplex detection, and mutant DNA cannot be detected in less than 5% of background of normal DNA.

Choi et al. (US 2007/0042400 A1), at paragraph 0035, teach:

[0035] In conventional methods of preparing nucleic acid, polysaccharides such as starch often co-precipitate with nucleic acid. When polysaccharides co-precipitate with nucleic acid, it is difficult to manipulate nucleic acids by amplification methods, such as PCR, or by other detection methods, such as hybridization detection. Polysaccharides may also inhibit digestion with restriction endonucleases and other enzymatic manipulations.

It is noted that the claimed method fairly encompasses the use of genomic DNA, and the use of an enzyme substrate as a label.

Yasuno et al., (US 2007/0031829 A1), paragraph 0037, teach in part:

Certain oligonucleotides hybridize to polynucleotides having complementary sequences. Although DNA hybridization is sequence-specific, it is difficult to completely exclude hybridizations towards very similar nucleotide sequences.

Wang et al., (US 2007/0009954 A1), teach:

[0004] A number of methods have been developed to score SNPs, including allele-specific hybridization, electrophoretic DNA sequencing, single-nucleotide extension using labeled chain terminators, the "Invader" assay (Third Wave Technologies, Madison

Art Unit: 1634

Wis.), mass spectrometry, the 5' nuclease assay (Taqman; see below), etc. All of these methods entail assays that are either difficult or expensive to develop, or difficult or expensive to perform.

Rowlen et al., (US 2006/0286570 A1) teach:

[0004] A variety of methods exist for detection of molecular recognition events. Detection of molecular recognition events such as DNA hybridization, antibody-antigen interactions, and protein-protein interactions becomes increasingly difficult as the number of recognition events to be detected decreases.

It is noted that the claimed method places no lower limit on the ability to accurately and reproducibly detect any binding between polymer and unit specific markers.

As evidenced above, the art is replete with known issues that directly impact the enablement of the claimed invention. A review of the instant disclosure fails to identify how these art-recognized issues are to be overcome such that the full scope of the invention can be practiced without the public having to resort to undue experimentation.

At column 40 of Jones (US Patent 5,858,671) the inherent obstacle in synthesizing oligonucleotide arrays is disclosed. As stated therein, “that even if the constituent enzymatic steps approach 100% completion, incompletely processed products can accumulate to significant levels. For example, during oligonucleotide synthesis of a 70-mer, requiring 69 couplings, a 99% coupling efficiency results in only 50% of the generated oligonucleotides being full length ( $0.99^{69} = 0.50$ ).” In the present case, applicant is claiming a product that would be the result of an infinite number of couplings, not just 69 as described above.

The instant disclosure fails to teach how these art-recognized issues are to be overcome. Absent such guidance, one of skill in the art is forced to conduct trial-and-error experimentation. In view of the thousands of man-years that have already gone into this area of research, there is little likelihood that these issues will all be overcome through the expenditure of only routine optimization such that the full scope of the presently-claimed invention can be practiced.

Assuming *arguendo* that these issues could be overcome, which is a position that the Office does not concede, the specification still does not provide the starting materials whereby any species of plant, virus, microbe, or animal can be “identified.”

Applicant, at page 12 of the response of 13 February 2009, direct attention to page 29, lines 6-11, of the specification, which states in part:

First, the extremely sharp melting transitions observed in nanoparticle oligonucleotide detection probes translate to a surprising and unprecedented assay specificity that could allow single base discrimination even in a human genomic DNA background.

There is no evidence of record that a gold nanoparticle alters the melting properties of DNA or any other nucleic acid. Accordingly, the issues of partial hybridization, primer-dimers, mis-priming, etc. that are known to occur in the art are expected to occur still.

Assuming *arguendo* that the gold nanoparticles do in some unexplained manner alter the hybridization kinetics, the specification still does not disclose how this is to be manipulated. Rather, the claims as presently worded do not distinguish between sizes of the nanoparticles; the length, composition and linking aspects of the probe to the nanoparticle; the chemical formulation of the nanoparticles; and how they can be made, so as to ensure the availability of an essential starting material.

It is noted that the passage cited by applicant speaks to what “could” take place, not to what can or does take place. The use of the forward-looking modifier “could” speaks to the invention not existing in readily available form at the time of filing. Aside from enabling the making and use of the invention, the specification must also describe the invention in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The reliance of applicant upon the use of forward-looking statements does not reasonably suggest that applicant had possession of the invention at the time of filing.

Breadth of claims

As presently worded, the claims encompass a method of detecting antibiotic-resistant *Staphylococcus* bacteria where the capture and detection probes share but a single nucleotide in common with the target. In support of this interpretation, it is noted that the capture and detection probes need only comprise but a "fragment" of the gene of interest. A single nucleotide is recognized as being a "fragment" of the gene.

Also, the claims fairly encompass a method of detection where no signal amplification occurs, the detection takes place with the unaided eye, the “detector probe” does not comprise any detectable label (the specification teaches that the gold particles were undetectable), unhybridized detector probe is not removed from the system prior to performing the detection step.

In accordance with claim 2, there is to be a single nucleotide polymorphism or SNP, but there is no requirement that the SNP be correlated with any resistance feature.

In accordance with claims 3, 4, and 6, the capture probe is capable of “recognizing” a SNP.

Such speaks to an inanimate compound performing an animate (cognitive) function.

In accordance with claim 13, the detector probe “allows [for] detection by photonic, electronic, acoustic, opto-acoustic, gravity, electro-chemical, electro-optic, mass-spectrometric, enzymatic, chemical, biochemical or physical means.” As addressed above, Example 4 only teaches use of a gold particle, which alone was undetectable, but that “In order to facilitate the visualization of nanoparticles hybridized to the substrate surface, a signal amplification method in which silver ions are catalytically reduced by hydroquinone to form silver metal on the slide surface was employed.” Such a showing clearly does not enable the myriad detection embodiments encompassed by the claims. It is further noted that claim 1, the sole independent claim, is not so limited and fairly encompasses additional means of detection.

Claims 168-172 fairly encompass performing additional nucleic acid assays, which are not necessarily limited to *Staphylococcus*. As can be seen in claim 169, one is to “distinguish between two or more species of a common genus.” The specification has not disclosed a multiplex assay, much less conduct a qualitative and/or quantitative assay.

In view of the breadth of scope claimed, the limited guidance provided, the unpredictable nature of the art to which the claimed invention is directed, and in the absence of convincing evidence to the contrary, the claims are deemed to be non-enabled by the disclosure.

Response to argument

9. At page 10 of the response of 13 February 2009, hereinafter the response, applicant asserts:

Applicants respectfully submit that the claims have been misapprehended. Neither the claim itself nor the specification limits the detecting to use of the naked eye. The detecting could occur by any means. Applicants respectfully direct the Examiner's attention to claims 13, 27-37 and pp. 29-31 of the specification in which alternative detection methods are described. Simply because the nanoparticles in Example 4 could not be visualized by the naked eye without signal amplification does not mean that unamplified nanoparticles could not be visualized using any of the other means described in the specification.

10. The above argument has been fully considered and has not been found persuasive.

Attention is directed to MPEP 904.01.

The breadth of the claims in the application should always be carefully noted; that is, the examiner should be fully aware of what the claims do not call for, as well as what they do require. During patent examination, the claims are given the broadest reasonable interpretation consistent with the specification. See *In re Morris*, 127 F.3d 1048, 44 USPQ2d 1023 (Fed. Cir. 1997). See MPEP § 2111 - § 2116.01 for case law pertinent to claim analysis.

Narrowing limitations found in the specification cannot be inferred in the claims where the elements not set forth in the claims are linchpin of patentability. *In re Philips Industries v. State Stove & Mfg. Co, Inc...*, 186 USPQ 458 (CA6 1975). While the claims are to be interpreted in light of the specification, it does not follow that limitations from the specification may be read into the claims. On the contrary, claims must be interpreted as broadly as their terms reasonably allow. See *Ex parte Oetiker*, 23 USPQ2d 1641 (BPAI, 1992). In the present case it is noted that claims 1-4, 6-8, 10, 113, 27, 28, 32-37, and 168-172 do not require the use of any detection means. While claims 32-37 do require one to measure conductivity, no correlation or conclusion from its measurement is to be drawn. Accordingly, the claims have been interpreted as encompassing detection by the use of the unaided eye.

11. At page 11 of the response applicant asserts that silver stain could be used to affect a signal that could be detected by the unaided eye. This argument is not persuasive as claims 1-4,

Art Unit: 1634

6-8, 10, 13, 27, 29-37, 168-172 do not require the use of any silver stain. Even in the case of claim 27, which does recite the use of a silver stain, the method of claim 1, from which it depends, does not require any removal of any unhybridized probes and as such, all of the gold nanoparticles and their associated probes would be present and would be expected to yield a silver precipitate, even if there is no target nucleic acid present.

12. At page 11, bridging to page 12 of the response applicant presents opinion argument as to what one of skill in the art would have been able to practice. This argument has not been found persuasive, as it is void of any factual underpinning. Attention is directed to MPEP 2145.

Attorney argument is not evidence unless it is an admission, in which case, an examiner may use the admission in making a rejection. See MPEP § 2129 and § 2144.03 for a discussion of admissions as prior art.

The arguments of counsel cannot take the place of evidence in the record. In re Schulze, 346 F.2d 600, 602, 145 USPQ 716, 718 (CCPA 1965); In re Geisler, 116 F.3d 1465, 43 USPQ2d 1362 (Fed. Cir. 1997) (“An assertion of what seems to follow from common experience is just attorney argument and not the kind of factual evidence that is required to rebut a prima facie case of obviousness.”). See MPEP § 716.01(c) for examples of attorney statements which are not evidence and which must be supported by an appropriate affidavit or declaration.

13. Applicant, at page 12 of the response of 13 February 2009, direct attention to page 29, lines 6-11, of the specification, which states in part:

First, the extremely sharp melting transitions observed in nanoparticle oligonucleotide detection probes translate to a surprising and unprecedented assay specificity that could allow single base discrimination even in a human genomic DNA background.

14. Applicant is seemingly asserting a secondary consideration as to the ability of the gold nanoparticles to significant and unexpected advantages. In so far as applicant’s arguments are to be construed as a secondary consideration, such are considered if the claims had been rejected under 35 USC 103(a). In the present case, however, the rejection is under 35 USC 112, first

paragraph, and secondary considerations cannot be relied upon to overcome a rejection be it based on non-satisfaction of enablement and/or non-satisfaction of written description requirement(s)

15. Turning to the basis of there being a new and widely-applicable property of gold nanoparticles to DNA and its hybridization, there is no evidence of record that a gold nanoparticle alters the melting properties of DNA or any other nucleic acid. Accordingly, the issues of partial hybridization, primer-dimers, mis-priming, etc. that are known to occur in the art are expected to occur still.

16. Assuming *arguendo* that the gold nanoparticles do in some unexplained manner alter the hybridization kinetics, the specification still does not disclose how this is to be manipulated. Rather, the claims as presently worded do not distinguish between sizes of the nanoparticles; the length, composition and linking aspects of the probe to the nanoparticle; the chemical formulation of the nanoparticles; and how they can be made, so as to ensure the availability of an essential starting material. Rather, the claims refer to “gold nanoparticles” in a general sense, without limit as to size, composition, linkages, coatings, etc. Such broadly applicable features speak to a property that is neither unexpected nor surprising.

17. It is noted that the passage cited by applicant speaks to what “could” take place, not to what can or does take place. The use of the forward-looking modifier “could” speaks to the invention not existing in readily available form at the time of filing. Aside from enabling the making and use of the invention, the specification must also describe the invention in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The

reliance of applicant upon the use of forward-looking statements does not reasonably suggest that applicant had possession of the invention at the time of filing.

18. for the above reasons, and in the absence of convincing evidence to the contrary, claims 1-4, 6-8, 10, 13, 27-37, and 168-172 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement.

### ***Conclusion***

19. Objections and/or rejections which appeared in the prior Office action and which have not been repeated hereinabove have been withdrawn.

20. All claims are drawn to the same invention claimed in the application prior to the entry of the submission under 37 CFR 1.114 and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the application prior to entry under 37 CFR 1.114. Accordingly, **THIS ACTION IS MADE FINAL** even though it is a first action after the filing of a request for continued examination and the submission under 37 CFR 1.114. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

21. A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however,

will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

22. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bradley L. Sisson whose telephone number is (571) 272-0751. The examiner can normally be reached on 6:30 a.m. to 5 p.m., Monday through Thursday.

23. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, Ph.D. can be reached on (571) 272-0735. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

24. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Bradley L. Sisson/  
Primary Examiner, Art Unit 1634